Solid Tumor, Adult Clinical Trial
Official title:
A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05054348 -
Phase 1b Study of IO-108 as Monotherapy and in Combination With a PD-1 Inhibitor in Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05055609 -
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04020185 -
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05865990 -
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
|
Phase 2 | |
| Withdrawn |
NCT05071846 -
MVX-ONCO-2 in Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05607199 -
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
|
Phase 1 | |
| Recruiting |
NCT04552288 -
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
|
Phase 2 | |
| Recruiting |
NCT05276284 -
Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04121442 -
Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04221204 -
A Monotherapy in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03992326 -
Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05435339 -
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04981119 -
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
|
||
| Recruiting |
NCT04092673 -
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05586321 -
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04899505 -
Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology
|
||
| Active, not recruiting |
NCT04597541 -
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04130516 -
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04041310 -
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
|
Phase 1/Phase 2 |